Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. The Drugs industry as a whole closed the day down 1.1% versus the S&P 500, which was down 0.1%. Laggards within the Drugs industry included ImmuCell ( ICCC), down 3.3%, EntreMed ( ENMD), down 3.1%, Reliv' International ( RELV), down 7.4%, NephroGenex ( NRX), down 4.3% and Chembio Diagnostics ( CEMI), down 3.9%. TheStreet Ratings Group would like to highlight 3 stocks that pushed the industry lower today: Chembio Diagnostics ( CEMI) is one of the companies that pushed the Drugs industry lower today. Chembio Diagnostics was down $0.13 (3.9%) to $3.20 on average volume. Throughout the day, 21,186 shares of Chembio Diagnostics exchanged hands as compared to its average daily volume of 20,300 shares. The stock ranged in price between $3.20-$3.34 after having opened the day at $3.34 as compared to the previous trading day's close of $3.33. Chembio Diagnostics has a market cap of $31.9 million and is part of the health care sector. Shares are down 1.2% year-to-date as of the close of trading on Thursday. Currently there are 3 analysts who rate Chembio Diagnostics a buy, no analysts rate it a sell, and none rate it a hold. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.